Merck KGaA acquisition of Silence Therapeutics

Description Merck KGaA has agreed to acquire Silence Therapeutics to add RNA-based rare-disease assets, including divesiran, to its pipeline. Overview Merck KGaA agreed to buy U.K. biotech Silence Therapeutics in an all-cash transaction reported at about $1.1 billion to $1.3 billion. Merck is offering $20 per American depositary… Read more